AtheroGenics to Present at Lehman Brothers Global Healthcare Conference March 18, 2008

ATLANTA, GA , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, will be presenting a company overview and update at the upcoming 11th Annual Lehman Brothers Global Healthcare Conference on Tuesday, March 18, 2008, at 3:45 p.m. Eastern Daylight Time at the Loews Miami Beach Hotel in South Beach, Florida.

A live audio webcast of the presentation will be available on the AtheroGenics Investor Relations Events website at http://www.atherogenics.com. A replay of the presentation will be available on the Company's website approximately twenty-four hours after the presentation and will be archived for thirty days.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). AtheroGenics has completed patient enrollment in ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study), a Phase III clinical trial evaluating its oral anti-inflammatory and antioxidant lead candidate, AGI-1067, in patients with diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

CONTACTS: AtheroGenics, Inc. Donna L. Glasky Corporate Communications 678-336-2517 Email Contact Media Inquiries Jayme Maniatis / Dana Conti Schwartz Communications, Inc. 781-684-0770 Email Contact Investor Inquiries Lilian Stern Stern Investor Relations, Inc. 212-362-1200 Email Contact

Atherogenics (NASDAQ:AGIX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024